Breast cancer treatment by Everolimus Therapy

Everolimus along with exemestane was approved for treating HER2 negative and HR-positive metastatic breast cancer after anastrozole or letrozole treatment had not shown successful. The results of this study showed that progression free survival was 4 months more for everolimus + exemestane treatment. The median PFS for exemestane + placebo group was 2.8 months as compares to everolimus + exemestane's 6.9 months.

Source: https://shorturl.at/fmCJ7

#EverolimusTherapy #BreastCancerTreatment #cancerresearch #MedicalInnovation #HealthcareAdvances #fightagainstcancer #WomenHealth #MedicalBreakthrough #Oncology #treatmentoptions #CancerTherapy